Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of anti-diabetes drugs with proven efficiency in the treatment of diabetes, which have recently shown striking results as weight loss medications, such that it is conceivable that long term use might be useful to prevent cancers associated with obesity. This evidence concerns the gene GLP1R and obesity disorder.